Literature DB >> 16538641

Serum level of sialic acid (SA) and carbohydrate-deficient transferrin (CDT) in type 2 diabetes mellitus with microvascular complications.

Bogdan Cylwik1, Lech Chrostek, Barbara Jakimiuk, Anna Popławska, Maciej Szmitkowski.   

Abstract

Sialic acid (SA) is responsible for the composition of different isoforms of transferrin and is reported to be a marker of microvascular complications in type 2 diabetes mellitus. Therefore, we explored the serum concentration of SA, and the less sialylated isoforms of transferrin, termed carbohydrate-deficient transferrin (CDT), in relation to the presence of microvascular complications in type 2 diabetes mellitus. We studied 21 patients with type 2 diabetes with microangiopathy and 22 patients without complications who were hospitalized at a diabetic clinic. The prevalence of microvascular complications was based on clinical history, fundoscopy, and laboratory tests. Blood samples were taken for measurements of SA, CDT, total transferrin, glucose, HbA1c, fibrinogen, C-reactive protein (CRP), and indicators of renal dysfunction (i.e., creatinine, urea, albumin excretion rate (AER), and glomerular filtration rate (GFR)). A rise in serum SA and a decrease in CDT concentrations were observed in both diabetic groups with and without complications, and there were no differences between the two groups of patients. There was a statistically significant correlation between serum SA and CDT in diabetic subjects with microvascular complications, but not in patients without such complications. This proves that the serum changes in CDT and SA levels in the course of type 2 diabetes mellitus are associated with each other in the presence of microangiopathy. (c) 2006 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16538641      PMCID: PMC6807578          DOI: 10.1002/jcla.20099

Source DB:  PubMed          Journal:  J Clin Lab Anal        ISSN: 0887-8013            Impact factor:   2.352


  24 in total

1.  Clinical significance of abnormal heterogeneity of transferrin in relation to alcohol consumption.

Authors:  H Stibler; S Borg; C Allgulander
Journal:  Acta Med Scand       Date:  1979

2.  Total and lipid-bound serum sialic acid in benign and malignant breast disease.

Authors:  J Romppanen; M Eskelinen; S Tikanoja; I Mononen
Journal:  Anticancer Res       Date:  1997 Mar-Apr       Impact factor: 2.480

Review 3.  Type 2 diabetes mellitus: a disease of the innate immune system? An update.

Authors:  M Crook
Journal:  Diabet Med       Date:  2004-03       Impact factor: 4.359

4.  Studies on glycosylated plasma proteins in diabetic patients.

Authors:  J Rehman; M A Rahman
Journal:  J Pak Med Assoc       Date:  1991-01       Impact factor: 0.781

5.  Raised serum sialic acid concentration in NIDDM patients with and without diabetic nephropathy.

Authors:  J Chen; M A Gall; H Yokoyama; J S Jensen; M Deckert; H H Parving
Journal:  Diabetes Care       Date:  1996-02       Impact factor: 19.112

6.  In vitro and in vivo alterations of enzymatic glycosylation in diabetes.

Authors:  N Rellier; D Ruggiero-Lopez; M Lecomte; M Lagarde; N Wiernsperger
Journal:  Life Sci       Date:  1999       Impact factor: 5.037

Review 7.  Occurrence of sialic acids in healthy humans and different disorders.

Authors:  P Sillanaukee; M Pönniö; I P Jääskeläinen
Journal:  Eur J Clin Invest       Date:  1999-05       Impact factor: 4.686

8.  Serum sialic acid and acute phase proteins in type 1 and type 2 diabetes mellitus.

Authors:  M A Crook; P Tutt; H Simpson; J C Pickup
Journal:  Clin Chim Acta       Date:  1993-10-15       Impact factor: 3.786

9.  Serum sialic acid, a risk factor for cardiovascular disease, is increased in IDDM patients with microalbuminuria and clinical proteinuria.

Authors:  M A Crook; K Earle; A Morocutti; J Yip; G Viberti; J C Pickup
Journal:  Diabetes Care       Date:  1994-04       Impact factor: 19.112

10.  The effects of streptozotocin diabetes on the activities of rat liver glycosyltransferases.

Authors:  H M Tepperman; J DeWitt; J Tepperman
Journal:  Diabetes       Date:  1983-05       Impact factor: 9.461

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.